Manni Mohyuddin Profile picture
Jun 4 7 tweets 4 min read
Theres a lot of talk about "top 5 or top 10" abstract lists at #asco2022 and a lot of hype.

In this 🧵, I highlight 5 flawed myeloma studies. I mean no offense to the well intentioned investigators, but do this to encourage critical inquiry and debate.

Read on.

#mmsm
1
meetings.asco.org/abstracts-pres…
KRD maint vs len maint post auto

Those that were MRD positive paid the "MRD tax" in a big way- 36 months of coming to the infusion center twice a week.

With an endpoint of PFS and comparison of 3 vs 1, result guaranteed.

Wonder what QOL was in K arm?
2
Dara-RVD for smoldering.

SO PROBLEMATIC.

What does "MRD' negativity even mean in someone with smoldering myeloma? Why should the results of this trial matter any more than the dozens of other duplicative small trials? How can you cure some people who WERE NOT gonna progress?
3
LOCOMOTION

Janssen did not need to do this for teclistamab. It is promising. But they compare different patients in different countries recieving outdated/inferior regimens and then say teclistamab is great. Come on Janssen, do better. "External" controls are so problematic.
4) A comparison of teclistamab vs physicians choice in patients who had progressed on trials.

Rather than highlight how good tec is, this draws attention to how bad therapy is for patients once the sponsor is done with the trial.
TECLISTAMAB DOES NOT NEED SUCH COMPARISONS.
5) Another comparison of teclistamab- this time with flatiron data.

Again, comparing trial patients to those in community from older times (2011 onwards)🙄 receiving outdated tx.
I want us all to ponder how 3 of the limited num of posters were useless teclistamab comparisons that serve only as marketing, and dont help patients or move field forward. Let us all do better. Also dont use KRD maintenance (for stnrd risk), and dont do DRVD for smoldering.
END.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Manni Mohyuddin

Manni Mohyuddin Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ManniMD1

Jun 5
The ATLAS trial presented at #ASCO22
-Given design (3 drugs maint, and PFS as endpoint), answer was obvious.
-Low power to detect any survival difference
-No quality of life presented, suspect would be worse if properly measured in KRd arm
-Please don’t adopt in practice! #mmsm ImageImageImageImage
Other thoughts:
-induction suboptimal by US standards, suspect benefit would be even less if len was given. Remember- that len based consolidation helps if induction regimen did not contain len (emn02-h095), but does NOT help if induction regimen contains len (STAMINA trial) Image
Presenter described treatment as well tolerated. There was a treatment related death in KRd arm. After randomization, 5 patient in len arm withdrew due to “patient decision/other” but 16 withdrew in KRd arm.

That’s informative censoring.And likely because KRd was tough to handle
Read 4 tweets
May 26
JUST OUT: ATLAS study #ASCO22.

A 🧵

KRD versus Len maint after auto-SCT in #mmsm

Better PFS with KRD (no surprise, you add effective agent to maintenance of course you get greater PFS, we didnt need a trial for that)

Some important themes to note

meetings.asco.org/abstracts-pres…
A commendable point of this trial is that those who were became MRD negative, were taken off KRD maintenance after 8 months of KRD maintenence.

Those who did not achieve MRD negativity (what a punishment)- were subjected to 3 years of maintenance therapy 😟
I have said this before, as have many people wiser than I have.

To change maintenance strategies (especially for standard risk patients)- you have to show an overall survival advantage. You have to show the disease trajectory is changed.
Read 9 tweets
May 16
Heres an educational 🧵 about me-too drugs using isatuximab as a case example. Dedicated to patients trying to separate hype from reality, and trainees seeking to make sense of so many new approvals for the disease states they are seeing.

#mmsm
What is a me-too drug?

It is a medication that is similar to a pre-existing drug with a similar mechanism of action but some minor tweaks that "may" change efficacy or toxicity.
Why do so many me-too drugs exist?

It is a much safer route for pharma companies to make money by modifying an existing product rather than promoting a brand new drug with a new mechanism of action that may or may not work/be safe.
Read 22 tweets
Mar 28
Prophylactic anticoagulation and risk of DVT in myeloma- a 🧵 on the evidence, a few case vignettes, and some guidance (based on VERY imperfect evidence).

Read on.
#mmsm #medtwitter
Firstly, let's establish 4 facts.

1) DVT is a PROBLEM in MM. Those who develop DVT have 3x risk of mortality compared to those who don't.
pubmed.ncbi.nlm.nih.gov/22511493/

2) DVT is COMMON- Incidence varies dramatically based on studies, but ~ 3-15% of patients develop it.
3) DVT risk is HIGHEST within first 6 months of diagnosis.

In an analysis of two large randomized trials including both transplant eligible and transplant ineligible patients, DVT occurred almost exclusively in first 6 months.

ashpublications.org/blood/article/…
Read 20 tweets
Mar 9
In honor of myeloma action month, heres a tweetorial on diagnosis of various plasma cell dyscrasias. It is a long interactive one with polls, so be prepared. It is geared towards trainees, oncologists who don't see a lot of myeloma, and other medicine specialties.
🧵 #mmsm
Also, you wont get CME for this, but I don't get paid for this either. Sometimes the best things in life are free (with no hidden agenda for promoting a drug), and you don't (or shouldn't) get paid for them 😀 There are some simplifications here (given Twitter)
Q1. A 47 yr old M with a creatinine of 2.1 (new/?etiology) is referred to you. Mild proteinuria (500mg/day). CBC normal. SPEP shows M protein of 1.8 g/dl, IFE -ve. Kappa light chain is 200 mg/L, ratio=11,BM biopsy with 5% monoclonal plasma cells. PET/CT -ve. Diagnosis?
Read 20 tweets
Dec 25, 2021
🎄tweetorial

Is MGUS more common in patients with osteoporosis? Do patients with MGUS have lower bone density? Should patients with osteoporosis be screened for MGUS? Or patients with MGUS screened for osteoporosis? What does the data (and guidelines) say?
🧵
#mmsm #medtwitter
We know from work done by the gurus of myeloma- that fractures are more common in patients with mgus than general population

But are fractures because of decreased done density or existing osteoporosis? We didn’t know.

pubmed.ncbi.nlm.nih.gov/14753733/
More work from the Mayo Group did also show that patients with MGUS had a slightly higher risk of osteoporosis, but you can see- the RR was 1.2 with 95% CI of 1.0-1.4.
pubmed.ncbi.nlm.nih.gov/19648385/
Read 20 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(